INCY — INCYTE CORP
—
Nasdaq ·
Health Care ·
Life Sciences Tools & Services ·
CIK 879169 ·
Last close
$99.75
Market Cap
$19.93B
52W High
$110.34
52W Low
$89.25
ADV30
1,649,312
Next earnings
2026-07-28
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 1,272,676,000 | 1,168,176,000 | 324,173,000 | 303,330,000 | 7,339,113,000 | 3,461,114,000 | 1,716,266,000 |
| Dec 2025 | 1,506,835,000 | 1,385,735,000 | 383,963,000 | 299,279,000 | 6,957,973,000 | 3,097,817,000 | 1,790,495,000 |
| Sep 2025 | 1,365,980,000 | 1,266,980,000 | 431,296,000 | 424,169,000 | 6,330,356,000 | 2,455,006,000 | 1,679,162,000 |
| Jun 2025 | 1,215,529,000 | 1,136,729,000 | 310,812,000 | 404,999,000 | 5,821,354,000 | 1,954,969,000 | 1,650,451,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$1,516,782,000
Investing CF
$-191,910,000
Financing CF
$198,537,000
CapEx
$-95,898,000
Dividends Paid
—
Buybacks
$-103,000
EPS Diluted TTM
$7.08
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$517,099,000
Inventory
$115,624,000
Receivables
$1,051,499,000
ST Investments
$554,711,000
EBIT TTM
$1,776,198,000
Pretax Income TTM
$1,773,861,000
Interest Exp TTM
$2,337,000
Analysts
22
Yahoo Snapshot (yfinance, live)
Total Revenue
$5,361,019,904
EBITDA
$1,548,935,040
Free Cash Flow
$558,867,008
Enterprise Value
$16,397,388,800
Total Cash
$4,015,824,896
Total Debt
$39,430,000
Shares Out
199,782,155
Trailing EPS
$7.08
Book Value
$28.12
ROE
30.8%
ROA
13.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 5,141,242,000 | 1,342,790,000 | 1,286,650,000 | 6,957,973,000 | 1,790,495,000 | — | 1,413,498,000 |
| Dec 2024 | 4,241,217,000 | 101,294,000 | 32,615,000 | 5,444,322,000 | 1,996,694,000 | — | 335,337,000 |
| Dec 2023 | 3,695,649,000 | 655,358,000 | 597,599,000 | 6,782,107,000 | 1,592,270,000 | — | 496,487,000 |
| Dec 2022 | 3,394,635,000 | 591,626,000 | 340,660,000 | 5,840,984,000 | 1,470,865,000 | — | 969,941,000 |
TTM Snapshot
Revenues TTM
$3,693,186,000
NetIncome TTM
$572,239,000
OpCashFlow TTM
$0
Assets (Latest)
$5,444,322,000
Forward EPS
$9.16
Max Pain — expiry 2026-06-18
max pain strike: $100.00 · spot: $99.75 · call oi: 4,736 · put oi: 5,778
Expected Move to 2026-06-18:
±$2.75
(2.76%) —
implied range
$97.00 –
$102.50
· ATM straddle on $100.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IQV | IQVIA HOLDINGS INC. | $29.90B | $179.17 | — |
| MEDP | Medpace Holdings, Inc. | $13.18B | $461.60 | — |
| ICLR | ICON PLC | $10.99B | $143.54 | — |
| CRL | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | $8.90B | $184.79 | — |
| IDXX | IDEXX LABORATORIES INC /DE | $45.20B | $573.00 | — |
News headlines (Yahoo Finance, 1h cache)
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)
2026-06-16 07:55 · Yahoo
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review
2026-06-15 14:43 · Yahoo
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
2026-06-14 20:35 · Yahoo
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essenti
2026-06-13 15:15 · Yahoo
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progr
2026-06-13 10:00 · Yahoo
Incyte Buys Vega To Add Late Stage Von Willebrand Disease Opportunity
2026-06-12 03:12 · Yahoo
Incyte Nears Buy Point As $1.25 Billion Acquisition Expands Offerings
2026-06-11 17:48 · Yahoo
Why Incyte (INCY) Stock Is Up Today
2026-06-10 20:33 · Yahoo
Intellia Therapeutics (NTLA) Down 7.9% Since Last Earnings Report: Can It Rebound?
2026-06-10 15:30 · Yahoo
2 S&P 500 Stocks for Long-Term Investors and 1 Facing Challenges
2026-06-10 13:53 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.